| Does flecainide regain its antiarrhythmic activity after electrical cardioversion of persistent atrial fibrillation? | |
| | |
MedLine Citation:
|
PMID: 15851308 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The purpose of this study was to evaluate the hypothesis that presumed reversion of electrical remodeling after cardioversion of atrial fibrillation (AF) restores the efficacy of flecainide. BACKGROUND: Flecainide loses its efficacy to cardiovert when AF has been present for more than 24 hours. Most probably, the loss is caused by atrial electrical remodeling. Studies suggest electrical remodeling is completely reversible within 4 days after restoration of sinus rhythm (SR). METHODS: One hundred eighty-one patients with persistent AF (median duration 3 months) were included in this prospective study. After failure of pharmacologic cardioversion by flecainide 2 mg/kg IV (maximum 150 mg in 10 minutes) and subsequent successful electrical cardioversion, we performed intense transtelephonic rhythm monitoring three times daily for 1 month. In case of AF recurrence, a second cardioversion by flecainide was attempted as soon as possible. RESULTS: AF recurred in 123 patients (68%). Successful cardioversion by flecainide occurred only when SR had been maintained for more than 4 days (7/51 patients [14%]). Failure to cardiovert was associated with a prolonged duration of the recurrent AF episode and concurrent digoxin use. Multivariate logistic regression confirmed that successful cardioversion was determined by digoxin use (odds ratio [OR] 0.093, P = .047) and by the interaction between the duration of SR and the (inverse) duration of recurrent AF (OR 6.499, P < .001). When flecainide was administered within 10 hours after AF onset and the duration of SR was greater than 4 days, the success rate was 58%. CONCLUSIONS: Flecainide recovers its antiarrhythmic action after cardioversion of AF. However, successful pharmacologic cardioversion occurs only after SR has lasted at least 4 days and is expected only for recurrences having duration of a few hours. Immediate pharmacologic cardioversion of AF recurrence may be a worthwhile strategy for management of persistent AF. |
| | |
Authors:
|
Robert G Tieleman; Isabelle C Van Gelder; Hans A Bosker; Tsjerk Kingma; Arthur A M Wilde; Charles J H J Kirchhof; Johan H Bennekers; Frank A L E Bracke; Nic J G M Veeger; Jaap Haaksma; Maurits A Allessie; Harry J G M Crijns |
Related Documents
:
|
11139938 - Treatment of mixed atrial fibrillation and typical atrial flutter by hybrid catheter ab... 8917258 - Improving survival for patients with atrial fibrillation and advanced heart failure. 19422588 - Long-term sinus rhythm stability after intraoperative ablation of permanent atrial fibr... 9622988 - Scope and efficacy of complex radiofrequency ablation. 23343688 - Predictors for efficacy of percutaneous mitral valve repair using the mitraclip system:... 22936588 - Twenty-three-hour stay loop ileostomy closures: a pilot study. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Heart rhythm : the official journal of the Heart Rhythm Society Volume: 2 ISSN: 1547-5271 ISO Abbreviation: Heart Rhythm Publication Date: 2005 Mar |
Date Detail:
|
Created Date: 2005-04-26 Completed Date: 2005-06-09 Revised Date: 2009-10-27 |
Medline Journal Info:
|
Nlm Unique ID: 101200317 Medline TA: Heart Rhythm Country: United States |
Other Details:
|
Languages: eng Pagination: 223-30 Citation Subset: IM |
Affiliation:
|
University Hospital Maastricht, The Netherlands. r.tieleman@fys.unimaas.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Anti-Arrhythmia Agents / pharmacology* Atrial Fibrillation / drug therapy*, physiopathology, therapy Electric Countershock* Female Flecainide / pharmacology* Humans Logistic Models Male Middle Aged Multivariate Analysis Prognosis Recurrence Time Factors |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents; 54143-55-4/Flecainide |
| Comments/Corrections | |
Comment In:
|
Heart Rhythm. 2005 Mar;2(3):231-3
[PMID:
15851309
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Atrioventricular conduction in mammalian species: hemodynamic and electrical scaling.
Next Document: T-wave alternans phase following ventricular extrasystoles predicts arrhythmia-free survival.